Leading the life sciences industry
Discover the 150+ academic medical centers, commercial labs, incubators, accelerators, and programs and services leading life sciences in New York State.
Funding
Investing in innovation
Careers
Your future starts here
The Latest
Regeneron’s Otarmeni™ Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss
Approval in severe-to-profound and profound OTOF-related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint, and with longer follow-up, 42% achieved normal hearing that included whispers. First FDA-approved example of a gene therapy to restore a neurosensory function to…
Mount Sinai Researchers Publish Landmark Cell Review Defining the “Hallmarks of Liver Cancer”
“This work brings together decades of research to better understand what drives liver cancer and how we can treat it more effectively. By applying the Hallmarks of Cancer framework, we connect the biology of these tumors with real therapeutic opportunities, helping guide more precise and personalized care.” -Josep M. Llovet, MD, PhD, Professor of Medicine…
Niagara University opens new biomedical research lab in Buffalo
Empire State Development (ESD) announced the completion of the Niagara University Biomedical Research Institute Laboratory on the Buffalo Niagara Medical Campus. The project was supported with a $78,750 grant from ESD’s Regional Council Capital Fund Program. The grant funds were used to purchase advanced research equipment and build offices and a research laboratory, including laboratory…
One Biosciences Establishes U.S. Operations in Albany
One Biosciences, based in Paris, France, will bring its proprietary technology to this first-of-its-kind hub in Albany to address the unmet clinical and scientific needs to characterize the tumor ecosystem. The company is developing technology to better understand each patient’s cancer, helping doctors around the world to match patients to the therapies most likely to…
Roswell Park Launches Exclusive CD83 CAR T-Cell Clinical Trial for Patients with Relapsed or Refractory AML
First time this CD83-targeting approach has been assessed in patients. Primary goal is to study the safety of the target and the CAR T cells. Research shows this therapy holds promise for treating AML and preventing GVHD.
LIFE SCIENCES IN NEW YORK
Where science and opportunity come together
New York’s life science sector has attracted unprecedented investment, expanded research clusters across the state, and nurtured the growth of early-stage companies.
70,000
LIFE SCIENCES JOBS
25%
CLINICAL TRIALS IN THE U.S.
60%
PHARMACEUTICAL HEADQUARTERS